Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05167864 · ClinicalTrials.gov registry record · NA
Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
NCT05167864: Completed NA study, sponsored by University of Pennsylvania.
NCT05167864 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05167864, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
Study Summary
The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.
Interventions
- DRUG Onabotulinumtoxina for Injection
- DRUG Abobotulinumtoxina for Injection
- DRUG IncobotulinumtoxinA for Injection
- DRUG PrabotulinumtoxinA for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05167864
The ClinicalTrials.gov registry entry for NCT05167864 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Onabotulinumtoxina for Injection is the first listed.
NCT05167864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05167864 about?
NCT05167864 is a clinical study titled "Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area". The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 month...
What is the current status of trial NCT05167864?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2022-03-04. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05167864?
The interventions under investigation include: Onabotulinumtoxina for Injection (DRUG), Abobotulinumtoxina for Injection (DRUG), IncobotulinumtoxinA for Injection (DRUG), PrabotulinumtoxinA for Injection (DRUG).
Who is sponsoring clinical trial NCT05167864?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.